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To the Editor
Since the end of February 2020 Italy, first non- Asian Country, has reported an ever increasing number of 
COronaVIrus Disease 19 (COVID-19) patients, which has reached over 200,000 confirmed Severe Acute 
Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) infected subjects, resulting in more than 34000 deaths 
(data updated to June 19th, 2020 1).
Patients with asthma are potentially more severely affected by SARS-CoV-2 infection and respiratory 
viruses are known to be associated with severe adverse asthma outcomes, including increased risk of 
asthma exacerbation episodes 2. Nonetheless, according to the epidemiological studies published so far, 
asthma is not amongst the most common clinical conditions in COVID-19 patients 3
About 5-10% of asthmatics are severe 4 and one would expect increased vulnerability to SARS-CoV-2 
infection, but no data is so fare available to confirm this hypothesis.
We investigated the incidence of COVID-19, describing its clinical course, in the population of the Severe 
Asthma Network in Italy (SANI), one of the largest registry for severe asthma worldwide 5, and in an 
additional Center (Azienda Ospedaliero Univeristaria di Ferrara, Ferrara, Italy). All centers, have been 
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symptoms, laboratory findings and lung imaging typical of COVID-19 but without access to 
nasopharyngeal or oropharyngeal swab specimens because of clinical contingencies/emergency) among 
their cohorts of severe asthma. Demographic and clinical have been obtained from the registry platform 
and collected from the additional Center. Additional data about COVID-19 symptoms, treatment and 
clinical course have been collected for all cases reported.
Ethical issues and statistical analysis are reported in the online supplementary material.
The entire severe asthmatics population accounted for 1504 patients, 65% of them were treated with 
biologicals (anti-IL5 or anti-IL5R agents: 52.9%, anti-IgE: 47.1%). Twenty-six (1.73%) patients had 
confirmed (11) or highly suspect COVID-19 (15); eighteen (69.2%) were females and mean age was 56.2 ± 
10 years. The geographical distribution of COVID-19 cases is presented in Figure 1.
Nine (34.6%) infected patients experienced worsening of asthma during the COVID-19 symptomatic 
period; four of them needed a short course of oral corticosteroids for controlling asthma exacerbation 
symptoms.
The most frequent COVID-19 symptoms were fever (100% of patients), malaise (84.6%), cough (80.8%), 
dyspnea (80.8%), headache (42.3%) and loss of smell (42.3%). Four patients (15.3%) have been 
hospitalized, one of which in intensive care unit; among hospitalized patients, two (7.7%) died for COVID-
19 interstitial pneumonia (no deaths among the non-hospitalized patients).
Severe asthmatics affected by COVID-19, had a significantly higher prevalence of non-insulin-dependent 
diabetes mellitus (NIDDM) compared to non-infected severe asthma patients (15.4% vs 3.8%, p=0.002; 
odds ratio: 4.7). No difference was found in other comorbidities, however patients with severe asthma 
and NIDDM had a not statistically significant trend of higher BMI (31.9 vs 26.9, p=0.09), suggesting a 
possible interaction between obesity and NIDDM as risk factors for COVID-19 in severe asthmatics.
Twenty-one patients with COVID-19 were on biologicals: 15 (71%) on anti-IL-5 or anti-IL5R agents 
(Mepolizumab n= 13; Benralizumab n=2 - counting for the 2.9% of all severe asthmatics treated with anti-
IL5 in our study population) and 6 (29%) on anti IgE (Omalizumab - 1.3% of all severe asthmatics treated 
with omalizumab in our study population). 
Table I describes the 26 COVID-19 patients.
In conclusion, in our large cohort of severe asthmatics, COVID-19 was infrequent, not supporting the 
concept of asthma as a particularly susceptible condition to SARS-CoV2 infection. This is in line with the 









This article is protected by copyright. All rights reserved
rate in our cohort of patients was 7.7%, lower than in the general population (14.5% in Italy 1). These 
findings suggest that severe asthmatics are not at high risk of SARS-CoV-2 infection and of severe forms of 
COVID-19. There are potentially different reasons for this. Self-containment is the first, because of the 
awareness of viruses acting as a trigger for exacerbations, and therefore they could have acted with 
greater caution, scrupulously respecting social distancing, lockdown and hygiene rules of prevention, and 
being more careful in regularly taking asthma medications. 
Another possible explanation stands in the intrinsic features of type-2 inflammation, that characterizes a 
great proportion of severe asthmatics. Respiratory allergies and allergen exposures are associated with 
significant reduction in angiotensin-converting enzyme 2 (ACE2) expression 6, the cellular receptor for 
SARS-CoV-2.  Interestingly, ACE2 and Transmembrane Serine Protease 2 (TMPRSS2) (another protein 
mediating SARS-CoV-2 cell entry) have been found highly expressed in asthmatics with concomitant 
NIDDM 7, the only comorbidity that was more frequent reported in our COVID-19 severe asthmatics.
The third possible explanation refers to the possibility that inhaled corticosteroids (ICS) might prevent or 
mitigate the development of Coronaviruses infections. Severe asthmatics, treated with high doses of ICS 4, 
may have been protected from SARS-CoV-2 infection.
Noteworthy, among our case-series of severe asthmatics with COVID-19, the proportion of those treated 
anti-IL5 biologics was higher (71%) compared to those treated with anti-IgE (29%). Although the number 
of cases is too small to draw any conclusion, it is tempting to speculate that different biological 
treatments can have specific and different impact on antiviral immune response, as suggested for anti-IgE 
as protective for other viral infections 8. Moreover we may speculate of the consequence of blood 
eosinophils reduction induced by anti-IL5 agents, as more than 70% of infected patients were treated with 
them: eosinopenia has been reported in 52-90% of COVID-19 patients worldwide and it has been 
suggested as a risk factor for more severe COVID-19 9. So far, no other large series of severe asthmatics 
treated with biologicals infected by COVID-19 has been published, so our speculations on the role of 
biologicals in modulating the risk of COVID-19 need further evidence. 
In conclusion, in our large cohort of severe asthmatics only a small minority experienced symptoms 
consistent with COVID-19, and these patients had peculiar clinical features including high prevalence of 
NIDDM as comorbidity. Further real-life registry-based studies are needed to confirm our findings and to 
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TABLES:
Table I – Demographic and clinical characteristics of severe asthmatics with COVID-19.
AD: atopic dermatitis; ALB: albuterol; AMC: amoxicillin/clavulanate; AR: allergic rhinitis; AZM: azithromycin; BENRA: benralizumab; BX: bronchiectasis; Cax: 
ceftriaxone; CIP: ciprofloxacin; CRSsNP: chronic rhinosinusits without nasal polyps; CRSwNP: chronic rhinosinusitis with nasal polyps; CVD: cardiovascular 
diseases; GERD: gastroesophageal reflux disease; HCQ: hydroxychloroquine; HTN: hypertension; IBP: ibuprofen; ICS/LABA: Inhaled corticosteroids/Long-acting 
beta2-agonists; LAMA: long-acting muscarinic agents; LMWH: low molecular weight heparins; LPV/r: lopinavir/ritonavir; LTRA: leukotriene receptor antagonists; 
LVX: levofloxacin; MDD: major depressive disorder; MEPO: mepolizumab; MV: mechanical ventilation; NIDDM: non-insulin-dependent diabetes mellitus; NIV: 
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FIGURE LEGENDS:
Figure 1 – Geographical distribution of severe asthmatics with COVID-19 (number of cases within the red 
circles) and subjects with positive nasopharyngeal swab positive for SARS-CoV-2 within the general 
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